Original Research Article

Are taxane based regimens better than non-taxane fluoropyrimidine based regimens in advanced gastric cancer? Findings from an observational multicentre study, South India

Manjunath I. Nandennavar1*, Krishnakumar Rathnam2, Janarthinakani Murugesan3, Ganapathy S. Raman3, Vidhubala Elangovan4, Palanivel Chinnakali5, Shashidhar V. Karpurmath1

1Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Center, Bangalore, Karnataka, India
2Department of Medical Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
3Department of Medical Oncology, Madras cancer care foundation, Chennai, Tamil Nadu, India
4Department of Medical Oncology, Fenivi Research Solutions, Chennai, Tamil Nadu, India
5Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Dhanvantri Nagar, Puducherry, India

Received: 19 January 2021
Accepted: 25 January 2021

*Correspondence:
Dr. Manjunath I. Nandennavar,
E-mail: manjunathndr@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Capecitabine, 5 Fluorouracil, platinum agents and taxanes are either used alone or in combination in advanced gastric cancers (AGC). Data on tolerability and efficacy of these regimens are minimal. We aimed to report proportion of AGC patients opting for best supportive care upfront and tolerability and efficacy of taxane and non-taxane fluoropyrimidine based regimens from three oncology centers, South India.

Methods: Case records of AGC patients initiated on either taxane or non-taxane fluoropyrimidine based chemotherapy during May 2016 to Dec 2017 in three private tertiary cancer care centers across two states in south India were reviewed. Information on clinical characteristics, regimen used, radiological and clinical response, toxicity and its related hospital admissions were extracted. Statistical analysis was done by categorical variables that were summarized using proportions. Median survival was calculated using Kaplan Meier curves and comparison between the groups were done using log-rank test.

Results: Of 88 AGC patients, 27 patients (30.7%) opted for best supportive care; 19 and 41 patients received paclitaxel based and non-taxane fluoropyrimidine based regimens respectively. There was no statistically significant difference in pain symptoms, vomiting, hospital admissions and intensive care admissions between the two regimens. Median (inter quartile range) survival of patients receiving best supportive care, taxane based regimen and non-taxane fluoropyrimidine regimen were 3.1 (1.5-16.1), 7.4 (1.6-15.0) and 11.6 (3.2-29.3) months respectively. Median (range) survival on any chemotherapy was 10.3 (1.6-29.3) months and it was significantly higher compared to best supportive care (p<0.001)

Conclusions: AGC patients on chemotherapy had improved overall survival compared to stand alone best supportive care. Fluoropyrimidine based regimens offered better survival than taxane based regimen.

Keywords: Carboplatin, CMOG, Paclitaxel, Radiological response, Survival, SORT IT, Toxicity
INTRODUCTION

Globally, gastric cancers are the fifth most commonly diagnosed cancer with 1,000,000 cases in 2018 and the third leading cause of death accounting for 1 out of 12 deaths.1 Despite the advancements in multimodality treatment options, the survival continues to be dismal due to late presentation and systemic recurrence after curative treatment.1-4 Five year overall survival (OS) is 27%, however it is 3% for unresectable and metastic cancers and the same is observed in India as well.5-7 Chemotherapy is an important option for symptom relief in patients with advanced gastric cancer (AGC). When the general condition of the patient and the advanced stage of tumor render chemotherapy inefectual, ‘best supportive care’ is provided for symptom control.7-9 Globally, there is no consensus on standard regimen for chemotherapy in AGC.10-12 Evidence suggests that patients who received chemotherapy showed better OS compared to those who received best supportive care.8,10,13 Multiple cytotoxic chemotherapeutic agents like platinum agents, taxanes, fluoropyrimidines, irinotecan, anthracyclines, etoposide, monoclonal antibodies are active in AGC.14,15 Taxane and fluoropyrimidine (5-FU: 5Fluorouracil or Capecitabine) based regimens are commonly used in treating AGC. Combination of 5FU and Cisplatin are commonly used in first line chemotherapy of AGC.16-19 Administration of infusional fluoropyrimidine based regimens needs prolonged hospital admission and insertion of central venous access devices (CVADs) like peripherally inserted central venous catheter (PICC) or chemoport adding to the treatment costs.20 Patients with CVADs need regular care of device and management of complications of CVAD (infections, venous thrombosis, device dislodgment, device failure etc).21,22 Although 5FU based regimens are reported to have more gastrointestinal toxicity compared to other regimens, it is preferred in majority of the oncology centers in India.23-25 On the other hand, taxane based regimens (monotherapy or doublet protocols) have an advantage over fluoropyrimidines because of their dosage convenience, tolerability and ease of administration.14,26,27 Indian data on outcomes of taxane (especially paclitaxel) based first line chemotherapy regimen in AGC patients is scarce.28-30 Therefore, in this study, we aimed to assess the treatment outcomes, toxicity and overall survival between taxane and non-taxane fluoropyrimidine based regimens in patients with advanced gastric cancer and to characterize the proportion of patients opting for best supportive care upfront.

METHODS

It was a cohort study involving review of patient records. The study was conducted in three private tertiary cancer care centers across two states in south India namely Karnataka (Bengaluru) and Tamil Nadu (Chennai and Madurai). The cancer centrein Bengaluru is in a medical college and teaching hospital with a full-fledged oncology department. The other two centers are private hospitals in Tamil Nadu state with oncology units.

Study setting

Gastric cancer is managed according to the standard guidelines of National Comprehensive Cancer Network (NCCN) and European Society and Medical Oncology (ESMO) in the study centers.31 Only those patients who are fit and opt for chemotherapy are treated with one of the first line palliative chemotherapy regimens.

Study population

Adults diagnosed with AGC at the three study centres between May 2016 and December 2017 were included in the study. We included only patients who were initiated on treatment with either taxane based (monotherapy or combination with platinum agent) or non-taxane fluoropyrimidine based (Cape-ox: Capecitabine oxaliplatin, ECF: Epirubicin Cisplatin 5-FU, EOX: Epirubicin Oxaliplatin Capecitabine, FOLFOX: 5FU Leucovorin Oxaliplatin, 5-FU/LV: 5-Fluorouracil Leucovorin, single agent capecitabine) regimens.

Data variables and sources of data

Baseline clinical presentations, clinical response and radiological response were retrieved from patient records. Information on common toxicology criteria (CTC) grade 3 and 4 toxicities and its associated hospital admissions (ward and ICU) were collected. Date of diagnosis, date of initiation of chemotherapy and date of death/lost to follow-up were obtained.

Data analysis

Data were entered using Epicollect5 (a free mobile application for data collection, Imperial College, London) and were analyzed with STATA (version 12.1, copyright 1985-2011 StataCorp LP USA). Continuous variables were expressed as mean (SD). Categorical variables like gender, symptoms and type of regimen were expressed as proportions.

Patients opting for best supportive care, details on clinical response, radiological response and toxicity were summarized as proportion with 95% confidence interval (CI). The difference in the outcome variables between the two groups (taxane vs. non-taxane fluoropyrimidine) was assessed using chi-square test. The date of censoring for
survival was 31st March, 2019. Median duration of survival in each group was estimated using Kaplan-Meir curves and compared using log rank test. A p-value of less than 0.05 was considered as statistically significant.

RESULTS

Demographic and clinical characteristics

Among 88 patients with AGC, 64 (72.7%) were male and 24 (27.3%) were female with a mean (SD) age of 53(13) years (Table 1).

Of 88 patients, 27 patients (30.7% (95% CI: 21.3-41.4)) opted for best supportive care. Of 61 patients who received first line chemotherapy, 41(67.2%) patients received fluoropyrimidine based regimen, 19(31.1%) patients received taxane based regimen and one patient received Docetaxel 5FU Cisplatin (DCF) regimen. Treatment options chosen by the patients and their outcomes are described in Figure1.

Chemotherapy regimens and number of cycles

Details of first line chemotherapy regimens and the number of cycles administered are described in Table 2. Of 19 patients who received taxane based regimens, 12 patients (63.1%) received paclitaxel carboplatin, 6 patients (31.5%) received paclitaxel monotherapy and one patient was on docetaxel carboplatin. Of the 41 patients who received 5FU based regimen, 46.6% received capecitabine oxaliplatin.

Table 1: Demographic and clinical characteristics of patients with advanced gastric cancer registered in three cancer centres in South India, 2016-2018 (n=88).

| Variables          | Categories                  | Total (n=88) | Best supportive care (n=27) | Chemotherapy (n=61) |
|--------------------|-----------------------------|--------------|-----------------------------|---------------------|
|                    |                             | n (%)        | n (%)                       | n (%)               |
| Total              |                             | 88 (100.0)   | 27 (30.6)                   | 61 (69.4)           |
| Gender             | Male                        | 64 (72.7)    | 23 (35.9)                   | 41 (64.0)           |
|                    | Female                      | 24 (27.3)    | 4 (16.6)                    | 20 (83.3)           |
| Age (years)        | Mean (SD)                   | 53 (13.0)    | 55.8 (12.0)                 | 51.6 (12.8)         |
| BMI (kg/m²)        | Mean (SD)                   | 21 (4.1)     |                             |                     |
| ECOG PS            | 1                           | 62 (75.6)    | 10 (16.1)                   | 52 (83.8)           |
|                    | 2                           | 19 (23.2)    | 15 (78.9)                   | 4 (21.0)            |
|                    | Not recorded                | 6 (6.8)      | 1 (16.6)                    | 5 (83.3)            |
| Presenting symptoms| Abdominal pain (n=86)       | 83 (96.5)    | 25 (30.1)                   | 58 (69.8)           |
|                    | Nausea/vomiting (n=86)      | 65 (76.5)    | 21 (32.3)                   | 44 (67.6)           |
|                    | Anorexia (n=87)             | 72 (82.8)    | 25 (34.7)                   | 47 (65.3)           |
|                    | Abdominal distention (n=75) | 34 (45.3)    | 7 (20.5)                    | 27 (79.4)           |
|                    | Constipation (n=83)         | 29 (34.9)    | 15 (51.7)                   | 14 (48.2)           |
|                    | Diarrhoea                   | 1 (1.1)      | 0 (0)                       | 1 (100)             |
|                    | Others                      | 6 (6.4)      | 2 (33.3)                    | 4 (66.6)            |
| Comorbidty         | Diabetes mellitus           | 19 (21.6)    | 2 (10.5)                    | 17 (89.4)           |
|                    | Hypertension                | 9 (10.2)     | 0 (0)                       | 9 (100)             |
|                    | Ischemic heart disease      | 6 (6.8)      | 2 (33.3)                    | 4 (66.6)            |
|                    | Hb (gm/dl) Mean (SD)        | 10 (2.3)     | 13.8 (5.0)                  | 10.5 (3.5)          |
|                    | Alb (gm/dl) Median (IQR)    | 3.5 (1.5-9)  | 9 (6.5)                     | 3.5 (6.1)           |
| Site of lesion     | Proximal                    | 29 (34.5)    | 3 (10.3)                    | 26 (89.6)           |
|                    | Distal                      | 49 (58.5)    | 22 (44.8)                   | 27 (55.1)           |
| Metastatic site    | Peritoneum/ascites          | 56 (63.6)    | 19 (33.9)                   | 37 (66.0)           |
|                    | Non-regional lymph nodes    | 53 (60.0)    | 10 (18.8)                   | 43 (81.1)           |
Table 2: First line chemotherapy regimens and number of cycles received by patients with advanced gastric cancer registered in three cancer centres in South India, 2016-2018 (n=61)

| Chemotherapy regimen | Total | Number of cycles |
|-----------------------|-------|------------------|
|                       | N (%) | <3 3-5 <5 ≥6 |
| **Total**             | 61    | 100 15 11 35    |
| **Taxane based regimens (n=19)** |       |                 |
| Paclitaxel Monotherapy | 6     | 31.5 4 0 2     |
| Paclitaxel Carboplatin | 12    | 63.1 3 4 5     |
| Docetaxel Carboplatin  | 1     | -5.2 0 0 1     |
| **5FU based regimens (n=41)** |       |                 |
| Capecitabine Oxaliplatin | 19   | 46.3 2 3 14    |
| EOX/ECF                | 16    | -39 3 2 11    |
| FOLFOX                 | 1     | -2.4 0 0 1     |
| 5FU-LV                 | 1     | -2.4 0 1 0     |
| Single agent capecitabine | 4   | -9.7 3 1 0     |
| **Other (DCF)**        | 1     | 0 0 0 1       |

DCF – DocetaxelCisplatinum 5-Fluouracil, EOX/ECF – EpirubicinOxaliplatinCapecitabine/EpirubicinCisplatinum 5-Fluorouracil, FOLFOX - 5-Fluorouracil Leucovorin Oxaliplatin, 5-FU-LV - 5-Fluorouracil Leucovorin

Figure 1: Flow chart describing management and outcomes among patients with advanced gastric cancers in three cancer centres in South India, 2016-2018 (n=88).

Table 2: First line chemotherapy regimens and number of cycles received by patients with advanced gastric cancer registered in three cancer centres in South India, 2016-2018 (n=61)

| Chemotherapy regimen | Total | Number of cycles |
|-----------------------|-------|------------------|
|                       | N (%) | <3 3-5 <5 ≥6 |
| **Total**             | 61    | 100 15 11 35    |
| **Taxane based regimens (n=19)** |       |                 |
| Paclitaxel Monotherapy | 6     | 31.5 4 0 2     |
| Paclitaxel Carboplatin | 12    | 63.1 3 4 5     |
| Docetaxel Carboplatin  | 1     | -5.2 0 0 1     |
| **5FU based regimens (n=41)** |       |                 |
| Capecitabine Oxaliplatin | 19   | 46.3 2 3 14    |
| EOX/ECF                | 16    | -39 3 2 11    |
| FOLFOX                 | 1     | -2.4 0 0 1     |
| 5FU-LV                 | 1     | -2.4 0 1 0     |
| Single agent capecitabine | 4   | -9.7 3 1 0     |
| **Other (DCF)**        | 1     | 0 0 0 1       |

DCF – DocetaxelCisplatinum 5-Fluouracil, EOX/ECF – EpirubicinOxaliplatinCapecitabine/EpirubicinCisplatinum 5-Fluorouracil, FOLFOX - 5-Fluorouracil Leucovorin Oxaliplatin, 5-FU-LV - 5-Fluorouracil Leucovorin

Figure 1: Flow chart describing management and outcomes among patients with advanced gastric cancers in three cancer centres in South India, 2016-2018 (n=88).
Table 3: Toxicity related to Taxane and 5FU based chemotherapy and associated hospital admissions in patients with advanced gastric cancer registered in three cancer centres in South India, 2016-2018 (n=61).

| CTC grade 3 and 4 toxicity and hospital admission | Chemotherapy | P value |
|--------------------------------------------------|--------------|---------|
|                                                  | Taxane       | 5 FU    |        |
|                                                  | based (n=19) | based   |        |
|                                                  | (n=41)       |         |        |
| Hb (<8 gm/dl)                                   | 2            | 13.3%   | 5       | 16.7% | 0.81 |
| WBC (<3000)                                     | 9            | 50%     | 19      | 46.3% | 0.8  |
| Platelet count                                   | 1            | -5.6%   | 1       | -2.5% | 0.62 |
| Echo EF (<55%)                                   | 2            | 12.5%   | 2       | -6.5% | 0.53 |
| Neupathy                                         | 2            | 11.8%   | 13      | 33.3% | 0.07 |
| Mucositis                                       | 2            | 11.8%   | 12      | 32.4% | 0.12 |
| Vomiting episode (>1/24 hrs)                     | 0            | (-)     | 11      | 32.3% |
| ICU admission                                    | 1            | -5.9%   | 6       | 15.4% | 0.37 |
| Hospital admission                               | 7            | 43.8%   | 11      | 33.3% | 0.14 |

CTC-Common Terminology Criteria for adverse events, Hb-Hemoglobin (gram/decilitre), WBC-White Blood Cells, EF-Ejection Fraction, ICU-Intensive Care Unit, 5FU-5 Fluorouracil

Toxicity and hospital admissions

Grade 3 and 4 toxicity and related hospital admissions are presented in Table3. Hospital admissions were more among patients who received taxane based regimen (43.8% vs 33.3%; P= 0.14) and intensive care unit admissions were observed more among fluoropyrimidine based regimen group (15.4% vs 5.9%; P=0.37) but were not statistically significant. Similarly, there was no significant difference in any of the toxicities between the two regimens though patients who received fluoropyrimidine based regimen had more neuropathy, mucositis and vomiting episodes.

Clinical and radiological response

Symptomatic and radiologic responses to the first line chemotherapy regimens are described in Table4.

Table 4. Clinical and radiological imaging response to first line chemotherapy (Taxane and 5FU based) in patients with advanced gastric cancer registered in three cancer centres in South India, 2016-2018 (n=61).

| Variables | Categories | Clinical and radiological response | P value |
|-----------|------------|-----------------------------------|---------|
|           |            | Taxane-based (n=19)              | 5-FU-based (n=41) |        |
|           |            | Baseline | Post CT | Baseline | Post CT |        |
| Presence of symptoms | | N | N | N | N | (%) |
| Pain | 18 | 13 | -72.2 | 39 | 30 | -76.9 | 0.71 |
| Nausea/vomiting | 11 | 8 | -72.7 | 32 | 24 | -75 | 0.87 |
| Anorexia | 14 | 7 | -50 | 32 | 28 | -87.5 | 0.01 |
| Radiological imaging* | | n=8 | | n=32 | | |
| Overall response | - | 4 | -50 | - | 22 | -68.8 | 0.34 |
| CR | - | 2 | -25 | - | 2 | -6.2 |
| PR | - | 1 | (12.5) | - | 19 | -59.3 |
| Stable disease | - | 1 | -12.5 | - | 1 | -3.1 |
| Upper GI endoscopy** | | n=6 | | n=23 | | |
| Overall response | - | 3 | -50 | - | 19 | -82.6 | 0.15 |
| CR | - | 2 | -33.3 | - | 2 | -8.6 |
| PR | - | 1 | -16.6 | - | 15 | -65.2 |
| Stable disease | - | 0 | - | - | 2 | -8.6 |

There was no statistically significant difference in pain symptoms and vomiting between the two groups. In fluoropyrimidine group, 28 patients (87.5%) out of 32 had significant improvement in anorexia compared to 7(50%) out of 14 in taxane group (p=0.01). In fluoropyrimidine group, 22 out of 32 patients (69%) who were assessed for radiological response showed overall response; 19 (59%) showed partial response, 2 had complete response and one had stable disease. Among the 23 patients who underwent upper gastrointestinal endoscopy, 19 patients (83%) showed overall response; 15 (65%) had partial response, 2 had complete response and 2 patients showed stable disease.

Overall survival

The overall survival of patients opting for chemotherapy and best supportive care is depicted in Figure-2A.

Median (interquartile range) survival of patients receiving best supportive care, taxane based regimen and non-taxane fluoropyrimidine based regimen were 3.1 (1.5-16.1), 7.4 (1.6-15.0) and 11.6 (3.2-29.3) months respectively. The difference in median survival between taxane and fluoropyrimidine regimens was statistically significant (p<0.001). Median (range) survival of patients on any chemotherapy was 10.3 (1.6-29.3) months.
and it was significantly higher compared to best supportive care (p<0.001). Those who received second line chemotherapy (irrespective of type of first line therapy) had median survival of 13.5 (5.7-24.9) months compared to 7.7 (1.6-29.3) months in those receiving first line alone (p<0.001) (Figure-2B). The impact of number of cycles of chemotherapy given on overall survival of patients is depicted in Figure-2C and Figure-2D.

Statistically significant differences were observed based on number of chemotherapy cycles received in both taxane and fluoropyrimidine based regimen.

**DISCUSSION**

In our study, 70% of the AGC patients received chemotherapy upfront and had significantly better overall survival than patients who opted for best supportive care. Fluoropyrimidine based regimen had better overall survival compared to the taxane group. Among the patients who received non-taxane fluoropyrimidine-based regimens, those who received at least 6 or more cycles and among the taxane group, those who received more than 4 cycles had better overall survival.

This study adds on to the limited evidence regarding efficacy and tolerability of paclitaxel based therapy (monotherapy and doublet) as first line therapy in AGC patients in India. Selection bias inherent in retrospective studies is a limitation of our study.

Radiologic imaging and gastrointestial endoscopy were not performed in all patients due to financial constraints and logistic issues and hence there were missing data in assessment of radiological response. The small sample size in the taxane based regimen did not allow us to do adjusted analysis for overall survival. The mean age of patients in our study was 53 years, similar to other Indian studies.\(^\text{2,13,32}\) In our study, two fold higher prevalence of AGC has been observed in male gender in accordance with other Indian and global findings.\(^\text{1,5,23,32}\) Studies have shown that distal stomach cancer is most prevalent in European and Asian countries and our study had similar findings: 58.5% with distal followed by 34.5% with proximal.\(^\text{6,37,38,40-42}\) Abdominal pain was the most common symptom similar to other studies in contrast to some studies reporting anorexia and weight loss to be the most common presenting symptom.\(^\text{2,3,33,36,39,41}\)

In recent Indian studies, ECF has been administered for an average of 5 cycles, EOX with a median of 8 cycles and Cape Ox with a median 6.5 cycles.\(^\text{31,32,44}\) In our study, about 75% of patients received a minimum of 4 cycles of paclitaxel carboplatin consistent with other studies.\(^\text{28,45,46}\) Paclitaxel monotherapy has also been shown to have anti tumor activity in AGC.\(^\text{1,16}\) In our study, one-third of the patients in taxane based regimen (6 out of 19, 31.5%) received paclitaxel monotherapy due to financial constraints.

Grade 3 and 4 (CTC adverse event) mucositis has been reported to be 3% by Babu et al, and it was higher in the present study with 12% in taxane group and 32% in 5FU group. Prithviraj et al., reported 14.2% Grade 3 and 4 neutropenia, 3.7% neuropathy and 2.2% anemia.\(^\text{26}\) Neutropenia has been reported to be 40% and anemia 8% whereas in our study neutropenia was 46.3% and anemia was 16.7%.\(^\text{23,24,32}\)

On the other hand, patients put on chemotherapy did better because of the response rate obtained from the first line regimen.\(^\text{2,19}\) Higher response rate has been correlated with better overall survival.\(^\text{47}\) Some single agent chemotherapy agents show response activity in the range of 16-18% (oral etoposide, cisplatin, hydroxyurea, doxorubicin, epirubicin).\(^\text{14}\)

Single agent paclitaxel shows an overall response rate (ORR- CR+PR+ Stable disease) of 17-23% and single agent docetaxel shows ORR of 17-29%.\(^\text{29,48-50}\) Doublet regimens (paclitaxel carboplatin) showed an ORR of 33%, triplet regimens like ECF have a higher ORR like 71%.\(^\text{51}\) In our study, 50% of the patients who underwent response assessment in the taxane based regimen group were found to have overall response.

In a Phase II trial of paclitaxel carboplatin in advanced gastric cancer, combination resulted in 33% response rate in 27 patients, with a median survival of nine months.\(^\text{52}\) In our study, patients receiving taxane based regimens had a median overall survival of 7.4 months. Multitagent chemotherapy regimens have shown to have a better median OS when compared to single agent chemotherapy (8.3 vs 6.7 months).\(^\text{18}\) In our study, of the patients receiving fluoropyrimidine based regimen, 22 out of 32
patients (69%) who were assessed for radiological response showed overall response; 19 (59%) showed partial response, 2 had complete response and one had stable disease. These findings are encouraging and better than that reported in the previous studies.

A review study done on the efficacy of chemotherapy in AGC patients has revealed that chemotherapy increased the overall survival by 6.7 months in comparison to best supportive care which is analogous with our study where the median OS of chemotherapy receiving group was 11.4 months while it was 4.3 months with BSC group.8,14

CONCLUSION

To conclude, our study has demonstrated that non-taxane based fluoropyrimidine regimens offer better survival in AGC patients than taxane based regimens although there were no significant differences in the chemotherapy induced toxicity. Receiving chemotherapy in AGC patients had also substantially improved OS in comparison to the group that received standalone best supportive care. Further randomized trials with large sample size may provide evidence on the efficacy of non-taxane fluoropyrimidine and taxane based regimens in the management of AGC.

ACKNOWLEDGEMENTS

This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Program for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The specific SORT IT program which resulted in this publication was jointly developed and implemented by: Fenivi Research Solutions Private Limited, Chennai, India; The Union South-East Asia Office, New Delhi, India; and the Center for Operational Research, The Union, Paris, France. Mentorship and the coordination/facilitation of this particular SORT IT program was provided through Fenivi Research Solutions Private Limited, Chennai, India; The Union South-East Asia Office, New Delhi, India; the Center for Operational Research, The Union, Paris, France; JIPMER, Puducherry, India; AIIMS, Nagpur, India and Velammal Medical College Hospital and Research Institute, Madurai, India.

The specific SORT IT program which resulted in this publication was based on the data shared by the members of Collaborative Medical Oncology Group (C-MOG), India. We acknowledge Dr Arun Seshachalam, Consultant Medical Oncologist from GVN hospitals, Trichy, Tamil Nadu state, India, Mrs Niraimathi and Malini from Fenivi Research Solutions for editing and critically reviewing the manuscript.

Authors would like to thank Dr Arun Seshachalam, Consultant Medical Oncologist from GVN hospitals, Trichy, Tamil Nadu state, India, Mrs Niraimathi and Malini from Fenivi Research Solutions for editing and critically reviewing the manuscript.

Funding: The Collaborative Medical Oncology Group (CMOG), Vijayawada, India; Onco Club, Trichy, India and Cancer Research and Relief Trust (CRRT), Chennai, India

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver.2013;7:385-93.
3. Cutsem EV, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654-64.
4. Al-Batran SE, Jäger E, Scholz M. Chemotherapy for advanced gastric cancer. J Clin Oncol. 2007;25:729.
5. Barad AK, Mandal SK, Harsha HS, Sharma BM, Singh TS. Gastric cancer-a clinicopathological study in a tertiary care centre of North-eastern India. J Gastrointestinal Oncol. 2014;5:142-7.
6. Nandi A, Sinha S, Biswas P, Kar M. Clinicopathological profile of gastric cancer in a tertiary care hospital in Eastern India: A prospective 2 year study. Clin Cancer Investig J.2014;4:14.
7. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-8.
8. Glimelius B, Hoffman K, Haglund U, Nyrén O, Sjödén PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5(5):189-90.
9. Shi J, Gao P, Song Y, Chen X, Li Y, Zhang C, et al. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Sci Rep. 2017;7(1):5319.
10. Souza FDO, Carlos L, Antunes M, Humberto L. Review article palliative treatment of gastric adenocarcinoma. 2011;24:74-80.
11. Cutsem EV. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9(2):9-15.
12. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635-49.
13. Bittoni A, Maccaroni E, ScartoZZi M, Berardi R, Cascini S. Chemotherapy for locally advanced and
metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci. 2010;14.
14. Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Annals of oncology. 2004;15:1585-95.
15. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-33.
16. Kang B, Kwon O-K, Chung H, Yu W, Kim J, Kang BW, et al. Taxanes in the treatment of advanced Gastric Cancer. Molecules. 2016;21:651.
17. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced Gastric, or Gastroesophageal Adenocarcinoma. J Clin Oncol 2005;23:5660-7.
18. Cutsem EV, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
19. Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-93.
20. Bishop L, dougherty L, bodenham A, mansi J, crowe P, kibbler c, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol 2007;29:261-78.
21. Yi M, Kim I-R, Choi E-K, Lee S, Kwak M, Cho J, et al. Discomfort related to peripherally inserted central catheters in cancer patient. Asian Oncol Nurs. 2017;17:229.
22. Bouza E, Burillo A, Muñoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect. 2002;8:265-74.
23. Ganguly s, biswas b, ghosh j, dakhara d. metastatic gastric cancer: real world scenario from a developing country. South Asian J Cancer. 2018;7:171.
24. Bhat G. Retrospective study of oxaliplatin, leucovarin and 5 fluorouracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India. South Asian J Cancer. 2018;7:223-5.
25. Servarayan Murugesan C, Manickavasagam K, Chandramohan A, Jebaraj A, Jameel ARA, Jain MS, et al. Gastric cancer in India: epidemiology and standard of treatment. Updates Surg 2018;70:233-9.
26. Prithviraj GK, Baksh K, Fulp W, Meredith K, Hoffe SE, Shridhar R, et al. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. Dis Esophagus. 2015;28:782-7.
27. Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, et al. Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One. 2013;8:78544.
28. Prithviraj GK, Baksh KA, Fulp WI, Meredith KL, Hoffe SE, Shridhar R, et al. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer. J Clin Oncol. 2014;32(15):15070.
29. Shi J, Gao P, Song Y, Chen X, Li Y, Zhang C, Wang H, Wang Z. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Scientific reports. 2017;7:5319.
30. Chen X-L, Chen X-Z, Yang C, Liao Y-B, Li H, Wang L, et al. Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e60320.
31. Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol. 2017;10:263-71.
32. Babu K, Chaudhuri T, Lakshmaiah K, Dasappa L, Jacob L, Babu M, et al. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. Indian J Cancer. 2017;54:47.
33. Maji S, Saha ML, Kanwar KS, Das S. An epidemiological study of 50 consecutive cases of gastric cancer from a tertiary care hospital in West Bengal. Int Surg J. 2016;2:247-51.
34. Kabir MA, Barua R, Masud H, Ahmed DS, Islam MM, Karim E, Sarkar MN, Barman RC. Clinical presentation, histological findings and prevalence of Helicobacter pylori in patients of gastric carcinoma. Faridpur Medical College J. 2011;6:78-81.
35. Shrikhande S, Parikh P, Pault J, Patil P, Chilukuri S, Ganesh B, et al. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol. 2014;35:239.
36. Sushma J, Kartheek BVS, Lakshmi AB. Clinicopathological study of carcinoma stomach over a period of 5 years. Int J Res Med Sci. 2017;5:558.
37. Al-Saleh K, El-Sherify M, Bedair A, Nazmy N, Elbasmi A, Hussein A, et al. Clinicopathological criteria and prognostic factors in gastric adenocarcinoma in Kuwait. J Glob Oncol 2018;4(2):80.
38. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018;10:239-48.
39. Qurieshi MA, Masoodi MA, Kadla SA, Ahmad SZ, Gangadharan P. Gastric cancer in kashmir. Asian Pac J Cancer Prev. 2011;12:303–7.
40. Ibrahim M, Gilbert K. Management of gastric cancer in Indian population. Transl Gastroenterol Hepatol. 2017;2:64.
41. Yu X, Hu F, Li C, Yao Q, Zhang H, Xue Y. Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer. Onco Targets Ther. 2018;11:1037–44.
42. Yu X, Hu F, Li C, Yao Q, Zhang H, Xue Y. Clinicopathologic characteristics and prognosis of proximal and distal gastric cancer. Onco Targets Ther. 2018;11:1037.
43. Chavan SS. Spectrum of gastric neoplastic lesions: A Clinicopathological study in the region of North Karnataka. 3:20.
44. Kayal S, Pani C kumar, Biswajit D, Verma S, Sistla SC, Cyriac SL. Comparison of efficacy and safety of capecitabine and oxaliplatin (CAPOX) with epirubicin, oxaliplatin plus capecitabine (EOX) as first line treatment for advanced gastric cancer (AGC), a randomized clinical study. J Clin Oncol 2015; 33(15):15026.
45. Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, et al. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. The Korean journal of internal medicine. 2005;20:135.
46. Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): An open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277-87.
47. Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, et al. Medical management of gastric cancer: a 2017 update. Cancer Med. 2017;7(1):123-33.
48. Haller D, Misset J. Docetaxel in advanced gastric cancer. Anticancer Drugs. 2002;13.
49. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology-williston park then huntington the melville new york 2002;6(6):89-96.
50. Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, et al. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1; a multicenter retrospective study. Cancer Chemother Pharmacol. 2017 ;80:575-82.
51. Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol. 2006;12:204-13.
52. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, et al. Phase II Study of Paclitaxel and Carboplatin in Patients With Advanced Gastric Cancer. Am J Clin Oncol. 2003;26:37-41

Cite this article as: Nandennavar MI, Rathnam K, Murugesan J, Raman GS, Elangovan V, Chinnakali P, et al. Are taxane based regimens better than non-taxane fluoropyrimidine based regimens in advanced gastric cancer? Findings from an observational multicentre study, South India. Int J Res Med Sci 2021;9:423-31.